Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 123

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 123
---
 any new clinical reference laboratory facility opened by us would be subject to certification under the European Molecular Genetics Quality Network (“EMQN”) and/or the College of American Pathologists (“CAP”), which could take a significant amount of time and result in delays in our ability to resume operations. These challenges could be amplified if we or our joint ventures or other commercial partners seek to procure and maintain laboratory space in the United States and Latin American region as we pursue international expansion. In addition, Mexico is a seismic region. The inability to open the planned facility in Mexico, delays in opening such facility due to logistical complications or natural disasters, or failure to obtain required permits, licenses, or certifications, could result in increased costs and prevent us from realizing the intended benefits of the new facility. 36 We are unable to predict the extent to which potential pandemics or outbreaks of communicable diseases will adversely impact our business operations and financial results. Our operations, business and financial condition could be materially and adversely affected by epidemics and other outbreaks of communicable diseases, including the COVID -19pandemic, and by the economic and operational disruptions caused by the attempts of governmental entities to contain or flatten the spread of the disease. Global health concerns relating to COVID -19have negatively affected the macroeconomic environment, and the pandemic has significantly increased economic volatility and uncertainty. The COVID -19pandemic created significant, widespread and unprecedented volatility, uncertainty, and economic instability, disrupting broad aspects of the global economy, capital markets, our operations, our workforce and our supply chain. Many of these effects continue to varying degrees and further mutated variants and outbreaks globally or regionally continue to harm recovering consumer confidence and have led to renewed implementation of harsh preventative measures by local and regional governments and businesses. The level and nature of the disruption caused by a pandemic is unpredictable, may be cyclical and long -lastingand may vary from location to location. A pandemic could materially impact our business for an unknown period of time, including in the following ways: •reduced access for our sales team to potential customers; •a need to shut down or operate our Argentine Wet -Labat a minimum due to quarantine, disrupting our operations and product deliveries; •delays and/or cancellations of Rewell test kits and/or Heritas Diagnostics sample logistics, nutrigenetic coaching and/or medical geneticist appointments, and other operational procedures which may negatively affect orders for our products or services; •illness, quarantines, financial hardships, restrictions on travel and commerce, and supply chain disruptions, which may